ArticleBMC complementary medicine and therapies2026
The effectiveness of Annona muricata for improving induced oral candidiasis in gamma-irradiated rats.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is an appropriate treatment for malignancies but can impair antifungal defense, promoting oral candidiasis. Candida tropicalis is of particular concern in immunocompromised patients and its management remains challenging. This study evaluated the antifungal efficacy of Annona muricata and its potential synergistic effect with nystatin against induced oral candidiasis in gamma-irradiated rats.
methodsForty male albino rats were assigned to five groups: R (irradiated), RC (irradiated infected), RCN (treated with nystatin), RCA (treated with A. muricata), and RCNA (treated with both therapies). Antifungal activity against C. tropicalis isolated from human oral lesions was assessed. Infection was introduced on the dorsal tongue surface, and treatment was initiated 48 h after inoculation. Rats were sacrificed on days 7 and 10. Body weight, tissue fungal burden, histopathological changes, and scanning electron microscopic findings were evaluated.
resultsA. muricata and nystatin reduced fungal burden and improved mucosal healing, with nystatin performing slightly better as a single treatment. However, their combined use produced the greatest overall improvement in morphology, fungal counts, tissue integrity, and microscopic findings. Untreated infected group showed persistent severe lesions and high fungal load. These results demonstrate a more pronounced effect when both therapies are applied together.
conclusionsA. muricata may exert antifungal and tissue-protective effects in a gamma-irradiated rat model of oral C. tropicalis infection. Its combination with nystatin may further enhance fungal clearance, improve mucosal integrity, and better maintain body weight compared with either treatment alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.